CHINARES PHARMA3320.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, CHINARES PHARMA (3320.HK) trades at a P/E of 6.08x, P/B of 0.47x, P/S of 0.09x, and a dividend yield of 5.20%.
Longitudinal percentile comparison: P/E sits at the 2nd percentile over the trailing 10Y window (vs. 6th percentile over 3Y); P/B sits at the 4th percentile over the trailing 10Y window (vs. 6th percentile over 3Y); P/S sits at the 2nd percentile over the trailing 10Y window (vs. 6th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 13th percentile within its industry and the 24th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 5.20%, ranking at the 98th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 2.3 points of each other — a consistent signal from both angles. The P/E percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. CHINARES PHARMA operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 3320 · SEHK: 3320 · 3320
Want the full picture on whether CHINARES PHARMA (3320.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 6.08 | ||||||
| P/B (MRQ) | 0.47 | ||||||
| P/S (TTM) | 0.09 | ||||||
| Dividend Yield | 5.20% | ||||||
| Buyback + Div Yield | 5.20% |